Bicycle Therapeutics
BCYC
27 hedge funds and large institutions have $132M invested in Bicycle Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 18 → 27 (+9)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.75% less ownership
Funds ownership: 25.68% → 24.93% (-0.75%)
9% less capital invested
Capital invested by funds: $144M → $132M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$2.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.44M |
| 3 |
MAP
Moody Aldrich Partners
Marblehead,
Massachusetts
|
+$1.41M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$629K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$561K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVA
Atlas Venture Advisors
Boston,
Massachusetts
|
-$13.4M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$77K |
| 3 |
Morgan Stanley
New York
|
-$9.98K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$7.72K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.04K |
BCYC Hedge Fund Activity: Q4 2020 in Review
27 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q4 2020, worth a combined $132M — down 8.5% from $144M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BCYC positions and 0 closed out — a net gain of 10 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Axa, opening a new position worth an estimated $2.8M. The largest seller was Atlas Venture Advisors, cutting an estimated $13.4M.
- 27 institutional investors held Bicycle Therapeutics (BCYC) as of Q4 2020, up from 18 in Q3 2020.
- Funds reported $132M of Bicycle Therapeutics stock for Q4 2020, down 8.5% quarter-over-quarter.
- 10 funds opened new Bicycle Therapeutics positions in Q4 2020 and 0 closed out, a net change of +10 holders.
- The largest Bicycle Therapeutics buyer in Q4 2020 was Axa, an estimated $2.8M added.
- The largest Bicycle Therapeutics seller in Q4 2020 was Atlas Venture Advisors, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2020.